March 22, 2018 08:16 AM EDT
Pharma

Sun Phar­ma screech­es to the pso­ri­a­sis fin­ish line with FDA OK of Ilumya. Too bad ri­vals J&J and oth­ers beat them to it

Brittany Meiling

In the crowd­ed race to launch new ther­a­pies for pso­ri­a­sis, In­dia’s largest drug­mak­er Sun Phar­ma hus­tled to the fin­ish line Thurs­day with FDA ap­proval of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times